<?xml version="1.0" encoding="UTF-8"?>
<p>The combination of glasdegib with cytarabine/daunorubicin was well tolerated, with a safety profile consistent with those observed in patients with AML receiving intensive chemotherapy.
 <xref rid="ajh25238-bib-0001" ref-type="ref">1</xref>, 
 <xref rid="ajh25238-bib-0003" ref-type="ref">3</xref>, 
 <xref rid="ajh25238-bib-0005" ref-type="ref">5</xref>, 
 <xref rid="ajh25238-bib-0034" ref-type="ref">34</xref>, 
 <xref rid="ajh25238-bib-0036" ref-type="ref">36</xref>, 
 <xref rid="ajh25238-bib-0037" ref-type="ref">37</xref>, 
 <xref rid="ajh25238-bib-0040" ref-type="ref">40</xref>, 
 <xref rid="ajh25238-bib-0051" ref-type="ref">51</xref>, 
 <xref rid="ajh25238-bib-0052" ref-type="ref">52</xref> Additionally, the AEs observed with glasdegib in combination cytarabine/daunorubicin were similar to those reported for glasdegib in combination with LDAC,
 <xref rid="ajh25238-bib-0026" ref-type="ref">26</xref> as well as other SMO inhibitors, and the majority of muscle spasms, dysgeusia and alopecia AEs were grades 1 or 2.
 <xref rid="ajh25238-bib-0053" ref-type="ref">53</xref>, 
 <xref rid="ajh25238-bib-0054" ref-type="ref">54</xref>, 
 <xref rid="ajh25238-bib-0055" ref-type="ref">55</xref> The most frequently reported grade &gt; 3 treatment‐related AEs were febrile neutropenia and anemia, with the time to hematologic recovery in line with that previously reported in the literature for patients with AML who received cytarabine/daunorubicin on the 7 + 3 schedule.
 <xref rid="ajh25238-bib-0003" ref-type="ref">3</xref> No new safety signals were detected.
</p>
